With medical and security professionals in the U.S. and across the world searching for a quick, portable and effective way to screen for the Ebola virus, an American medical device company is seeking funding for emerging technology that could screen for Ebola and a host of diseases within minutes, simply by testing an individual's breath.
BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today announced a joint research and development agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary, to discover and develop novel nanomedicines for oncology.
Novavax, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, announced today that representatives of Novavax, along with a number of its research collaborators, will be making multiple oral presentations and poster presentations related to Novavax' RSV F-protein nanoparticle vaccine candidate (RSV F Vaccine) at the 9th International Respiratory Syncytial Virus Symposium to be held November 9 – 13, 2014 in Stellenbosch, South Africa.
Artificial platelet mimics developed by a research team from Case Western Reserve University and University of California, Santa Barbara, are able to halt bleeding in mouse models 65 percent faster than nature can on its own.
Researchers at the University of Missouri-Kansas City School of Pharmacy have developed a novel mucoadhesive hyaluronic acid (HA) nanofibre delivery system which could help to prevent the transmission of HIV.
Antibodies, in charge of recognizing and homing in on molecular targets, are among the most useful tools in biology and medicine. Nanobodies – antibodies' tiny cousins – can do the same tasks, for example marking molecules for research or flagging diseased cells for destruction. But, thanks to their comparative simplicity nanobodies offer the tantalizing prospect of being much easier to produce.
Australian biopharmaceutical company Specialised Therapeutics Australia (STA) is pleased to announce ABRAXANE® (nanoparticle albumin-bound paclitaxel) in combination with gemcitabine, will be reimbursed via the Pharmaceutical Benefits Scheme (PBS) for patients with metastatic pancreatic cancer from 1 November.
BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced the online availability of an abstract providing preliminary data from the Q3W arm of its ongoing Phase 2 study of BIND-014 in non-small cell lung cancer (NSCLC).
Novavax, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Novavax' H7N9 Virus-Like Particle Vaccine Candidate (H7N9 VLP) adjuvanted with Matrix-M™. The H7N9 VLP is being developed under the company's contract with the U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority (BARDA) (Contract No. HHSO100201100012C) for the development of Novavax' recombinant vaccines to address seasonal influenza and influenza strains with pandemic potential.
Freiburg researchers decipher the role of nanostructures around brain cells in central nervous system function
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.